PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations
- PMID: 20213081
- DOI: 10.1007/s10549-010-0806-2
PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations
Abstract
PALB2 is a recently discovered breast cancer susceptibility gene, and mutations in the gene have been demonstrated to confer about twofold higher risk of breast cancer. Truncating mutations in PALB2 gene have been identified in varied populations. However, PALB2's significance to breast cancer has not been investigated in the Korean population. In this study, we evaluated the frequency of PALB2 1592delT and 229delT mutations in 300 Korean breast cancer patients diagnosed with either familial or early-onset breast cancer. All patients were confirmed negative for BRCA1 and BRCA2 mutations. Neither 1592delT nor 229delT mutations was found in any of the study cohort. Our results imply that these mutations are absent or rare in Korean patients who are negative for BRCA1 and BRCA2 mutations. We found no evidence to recommend screening for these mutations in the Korean population. However, PALB2 mutations have been demonstrated infrequent and inhomogeneous across investigated populations. Thus, screening the whole PALB2 gene for novel mutations is required to elucidate its significance in predisposition to breast cancer in Korean women.
Similar articles
-
Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27. Breast Cancer Res Treat. 2009. PMID: 18302019
-
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.Breast Cancer Res Treat. 2009 Apr;114(3):457-62. doi: 10.1007/s10549-008-0036-z. Epub 2008 Apr 30. Breast Cancer Res Treat. 2009. PMID: 18446436
-
A recurrent mutation in PALB2 in Finnish cancer families.Nature. 2007 Mar 15;446(7133):316-9. doi: 10.1038/nature05609. Epub 2007 Feb 7. Nature. 2007. PMID: 17287723
-
Hereditary breast cancer: from molecular pathology to tailored therapies.J Clin Pathol. 2008 Oct;61(10):1073-82. doi: 10.1136/jcp.2008.057950. Epub 2008 Aug 4. J Clin Pathol. 2008. PMID: 18682420 Review.
-
[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].Salud Publica Mex. 2011 Sep-Oct;53(5):420-9. Salud Publica Mex. 2011. PMID: 22218796 Review. Spanish.
Cited by
-
Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.Int J Clin Oncol. 2016 Apr;21(2):270-275. doi: 10.1007/s10147-015-0906-4. Epub 2015 Sep 28. Int J Clin Oncol. 2016. PMID: 26411315
-
Exome sequencing in a breast cancer family without BRCA mutation.Radiat Oncol J. 2015 Jun;33(2):149-54. doi: 10.3857/roj.2015.33.2.149. Epub 2015 Jun 30. Radiat Oncol J. 2015. PMID: 26157685 Free PMC article.
-
PALB2 mutation in a woman with bilateral breast cancer: A case report.Mol Clin Oncol. 2017 Apr;6(4):556-560. doi: 10.3892/mco.2017.1189. Epub 2017 Mar 9. Mol Clin Oncol. 2017. PMID: 28413668 Free PMC article.
-
Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation.Fam Cancer. 2015 Sep;14(3):365-71. doi: 10.1007/s10689-015-9789-9. Fam Cancer. 2015. PMID: 25712764
-
PALB2: a novel inactivating mutation in a Italian breast cancer family.Fam Cancer. 2010 Dec;9(4):531-6. doi: 10.1007/s10689-010-9382-1. Fam Cancer. 2010. PMID: 20852946
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous